Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

G3, Caprion Partner on Global Cardiovascular Disease Biomarker Study

Published: Wednesday, February 26, 2014
Last Updated: Wednesday, February 26, 2014
Bookmark and Share
Caprion to identify blood-based protein markers for study.

Global Genomics Group (G3) and Caprion Proteomics, Inc. announce that they have entered into a collaboration agreement to investigate biological networks and pathways in order to discover novel biomarkers and pharmaceutical targets for cardiovascular diseases. Under the terms of the agreement, Caprion will identify blood-based protein markers for the GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) study. GLOBAL is the largest pan-omic study combining genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics with coronary computed tomographic (CT) angiography, an advanced imaging technology for phenotyping, which allows precise disease classification of patients.

Szilard Voros, M.D., chief executive officer and co-founder of G3, said,  "We will analyze 22 trillion data points from the precise CT phenotyping and the pan-omic analyses with specifically-developed systems and biology-based bioinformatics, allowing us to understand the root causes of cardiovascular disease and ultimately enable us to identify novel diagnostic biomarkers and therapeutic targets. Caprion's unbiased and targeted mass spectrometry-based proteomic platform will provide an in-depth assessment of plasma proteins to complement the other 'omic' approaches we are using in the GLOBAL study."

Caprion will utilize its CellCarta┬« technology, an industrialized proteomic platform designed for large-scale studies, which is comprised of sample preparation, mass spectrometry, bioinformatics and biological expertise, to analyse and measure differential expression of proteins in plasma samples from the patients enrolled in GLOBAL. The ability to monitor and quantify large numbers of proteins in complex samples is key to understanding and treating complex diseases such as cardiovascular disease.  Caprion's platform has successfully been deployed for the identification of novel biomarkers and drug targets in a wide range of diseases as well as to understand the mechanism and effect of novel therapeutics.

Martin LeBlanc, president and CEO of Caprion, commented, "Caprion is pleased to collaborate with G3, and we are proud to leverage our expertise in large-scale proteomics and personalized medicine to contribute to this landmark effort in such a clinically-relevant field."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

G3 Completes GLOBAL Study Patient Enrollment
Pilot data of single largest prospective pan-omic study to identify key biomarkers and central therapeutic targets for cardiovascular diseases.
Thursday, February 13, 2014
Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!